News

Children with psoriasis are more likely to be overweight, warranting closer monitoring and lifestyle modification, according to results of a study.

A mouse model indicates that a protein rich diet high in arginine and proline may improve chronic wound healing.

A compounding pharmacy at the center of a national outbreak of fungal meningitis has voluntarily recalled all of its products, including numerous drugs for treating skin conditions.

Sun Pharmaceutical Industries, based in India, will acquire DUSA Pharmaceuticals, aiming to advance into the dermatologic market in the United States.

Propranolol may be more effective than corticosteroids in treating infantile cutaneous hemangiomas, a new study suggests.

Spending on medications for age-related conditions such as aging skin, hair loss, mental alertness and sexual dysfunction ranked third in annual prescription drug costs of the commercially insured in 2011, according to a recent study.

A recent study links psoriasis with an increased incidence of diabetes.

The Food and Drug Administration has approved a supplemental new drug application for a topical local anesthetic cream to be used in superficial cosmetic procedures.

A routine blood test could help to predict a patient’s likelihood to survive an aggressive form of skin cancer, researchers say.

A new medical adhesive can be easily removed from delicate skin, resulting in less irritation and damage than traditional kinds of medical tape, according to a recent report.

Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.

NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.

Lumenis has launched an upgraded AcuPulse CO2 laser that offers four new modes of treatment. Now, AcuPulse with SuperPulse technology offers a total of 10 different modes for treating 34 aesthetic indications, the company reports.

Syneron Medical has initiated a global launch of the Gentle Pro-U series of upgradeable aesthetic laser systems.

Merz has promoted Hyunna Coelho to vice president, commercial excellence, a role in which she will be responsible for sales training and development, corporate communication, sales operations, market research, competitive intelligence, forecasting, and operational analytics for the company in the United States.

LEO Pharma plans to establish five long-term research collaborations in four countries by the end of 2013 in an effort to deliver new treatment options to dermatology patients.

Photocure plans to exit its Allumera cosmetic dermatology business in the United States, the company recently announced.

The Food and Drug Administration has approved a supplemental new drug application for Pliaglis (lidocaine 7 percent, tetracaine 7 percent), a topical anesthetic cream.

The Casualties of Cutting : Both government & private-payer reimbursements continue to decline. Will the care that dermatologists provide suffer? All about Apps Clinical Dermatology : Practical dosing tips provide strategies for optimizing psoriasis control with biologics Cosmetic Dermatology : ‘Sensitive skin’ remains a marketing term with no medical definition Cutaneous Oncology : New topical, systemic therapies may improve survival of patients with CTCL Practice Management : Don’t hurry through the EHR selection and purchasing process

With the presidential election behind us and myriad changes about to hit healthcare, dermatologists need to anticipate cuts in reimbursement by not only government, but also private, insurers. And if dermatologists are to combat the impact these declining reimbursements may have on their practices, they need to start implementing more aggressive patient education and retention efforts now.

Dermatologists and other eligible professionals (EPs), eligible hospitals and critical access hospitals (CAHs) can now review the upcoming meaningful use stage 2 requirements, now that the Centers for Medicaid and Medicare Services has announced its "final rule" for attestation of meaningful use (MU) stage 2.

Sensitive skin is really a marketing term that has no medical definition. It might amaze you to know that approximately 60 percent of consumers polled in a recent trends study consider themselves to possess sensitive skin.

A patient with complaints about Dr. Derm's medical assistant demanded a refund on his co-pay, then threatened to destroy the doctor's reputation online. The patient returned a week later with worsening cellulitis, Dr. Derm refused to see him. The patient later became septic and he filed a medical malpractice lawsuit. What did Dr. Derm do wrong?

Belotero Balance (Merz), one of the newer hyaluronic acid (HA) fillers, appears to rival other longer-standing dermal fillers in efficacy and safety, offering physicians and their patients a new treatment option for the Aesthetic correction of moderate-to-severe facial wrinkles and folds, says Derek H. Jones, M.D.

Some of the continuing challenges central to the management of cutaneous T-cell lymphoma (CTCL) include improving the survival and prognosis of patients, as well as helping to make proposed treatments more affordable and accessible, says Elise A. Olsen, M.D.

The use of ultraviolet (UV) rays to dry nail polish can spell potential danger for patrons of nail salons, according to Joel Schlessinger, M.D., F.A.A.D., F.A.A.C.S., a board-certified dermatologist and cosmetic surgeon in Omaha, Neb.

Despite the number of currently available options for the treatment of actinic keratoses (AKs), dermatologists are still challenged by the occasional patient with widespread lesions refractory to multiple modalities.

If dermatologists considered the management of autoimmune blistering disorders from the patient's perspective, they might do many things differently. So says John Zone, M.D., co-director of the immunopathology lab at the University of Utah, where he is also chairman of dermatology.

The use of newer and more targeted chemotherapeutic agents can lead to atypical side effects affecting the skin, hair and nails of oncology patients, and these side effects can be different from those typically seen with longer-standing agents, says Beth N. McLellan, M.D., Ronald O. Perelman Department of Dermatology, New York University, New York.

Daniel M. Siegel, M.D., is best known in dermatology as president of the American Academy of Dermatology. But this practicing dermatologist and faculty member at State University of New York Health Sciences Center at Brooklyn says he thinks of himself as a "techie guy."